바로가기  >

Abstract
Recently, CRISPR proteins have been recognized as promising candidates for drug development. However, there is still a lack of substances with the appropriate sensitivity and stability for targeted drug delivery systems. 89Zr is a radioactive isotope that emits positrons, allowing real-time in vivo tracking with proven safety. In this study, we confirmed that labeling with 89Zr did not compromise the functionality of CRISPR proteins during in vivo behavioral imaging. Furthermore, we demonstrated the therapeutic efficacy of the CRISPR interference system in a mouse model of liver fibrosis, highlighting the theragnostic potential of isotope-labeled CRISPR proteins. The findings of this research could contribute to various aspects of ongoing clinical studies exploring the in vivo applications of CRISPR proteins.

Affiliations

Injoo Hwang 1, Jun Young Lee 1, Tae-Hyun Kim 1, Eun Ju Lee 2, Jeeho Kim 3, Hyomin Park 4, Min Goo Hur 1, Sanghwa Lee 5, Jeong-Hoon Park 6
1Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Republic of Korea.
2Biomedical Research Institute, Seoul National University Hospital, Republic of Korea.
3Department of Pharmacology, Chosun University School of Medicine, Republic of Korea.
4Molecular Medicine & Biopharmaceutical Sciences, Seoul National University, Republic of Korea.
5Department of Medical Life Science, Catholic University of Korea College of Medicine, Republic of Korea.
6Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Republic of Korea. Electronic address: parkjh@kaeri.re.kr.